Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

Joanne Kotsopoulos, Jan Lubinski, Susan L. Neuhausen, Henry T. Lynch, Barry Rosen, Peter Ainsworth, Pal Moller, Parviz Ghadirian, Claudine Isaacs, Beth Karlan, Ping Sun, Steven A. Narod

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objective. Hormone replacement therapy (HRT) is commonly prescribed to alleviate the climacteric symptoms of menopause. Recent findings from the Women's Health Initiative has raised questions about the routine use of HRT due to the increased observed incidence of cardiovascular disease and of breast and ovarian cancers in the treatment arm of the trial. In the general population, the association between HRT use and risk of ovarian cancer has not yet been resolved. This association has not been evaluated in BRCA1 or BRCA2 mutation carriers who face very high lifetime risks of both breast and ovarian cancers. Methods. We conducted a matched case-control study on 162 matched sets of women who carry a deleterious mutation in either the BRCA1 or BRCA2 gene. Women who had been diagnosed with ovarian cancer were matched to control subjects by mutation, year of birth, and age at menopause. Information on HRT use was derived from a questionnaire routinely administered to women who were found to be carriers of a mutation in either gene. Conditional logistic regression was used to estimate the association between HRT use and the risk of ovarian cancer, stratified by mutation status and type of HRT. Results. Compared with those who had never used HRT, the odds ratio associated with ever use of HRT was 0.93 (95% CI = 0.56-1.56). There was no significant relationship with increasing duration of HRT use. There was a suggestion that progestin-based HRT regimens might protect against ovarian cancer (odds ratio = 0.57) but this association was not statistically significant (P = 0.20). Conclusion. HRT use does not appear to adversely influence the risk of ovarian cancer in BRCA mutation carriers.

Original languageEnglish
Pages (from-to)83-88
Number of pages6
JournalGynecologic Oncology
Volume100
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Hormone Replacement Therapy
Ovarian Neoplasms
Mutation
Menopause
Odds Ratio
BRCA2 Gene
Breast Neoplasms
BRCA1 Gene
Women's Health
Progestins
Case-Control Studies
Cardiovascular Diseases
Logistic Models
Parturition

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology
  • Oncology

Cite this

Kotsopoulos, J., Lubinski, J., Neuhausen, S. L., Lynch, H. T., Rosen, B., Ainsworth, P., ... Narod, S. A. (2006). Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecologic Oncology, 100(1), 83-88. https://doi.org/10.1016/j.ygyno.2005.07.110

Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. / Kotsopoulos, Joanne; Lubinski, Jan; Neuhausen, Susan L.; Lynch, Henry T.; Rosen, Barry; Ainsworth, Peter; Moller, Pal; Ghadirian, Parviz; Isaacs, Claudine; Karlan, Beth; Sun, Ping; Narod, Steven A.

In: Gynecologic Oncology, Vol. 100, No. 1, 01.2006, p. 83-88.

Research output: Contribution to journalArticle

Kotsopoulos, J, Lubinski, J, Neuhausen, SL, Lynch, HT, Rosen, B, Ainsworth, P, Moller, P, Ghadirian, P, Isaacs, C, Karlan, B, Sun, P & Narod, SA 2006, 'Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers', Gynecologic Oncology, vol. 100, no. 1, pp. 83-88. https://doi.org/10.1016/j.ygyno.2005.07.110
Kotsopoulos, Joanne ; Lubinski, Jan ; Neuhausen, Susan L. ; Lynch, Henry T. ; Rosen, Barry ; Ainsworth, Peter ; Moller, Pal ; Ghadirian, Parviz ; Isaacs, Claudine ; Karlan, Beth ; Sun, Ping ; Narod, Steven A. / Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. In: Gynecologic Oncology. 2006 ; Vol. 100, No. 1. pp. 83-88.
@article{8baf80425ddb4117a44aaceaedb94513,
title = "Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers",
abstract = "Objective. Hormone replacement therapy (HRT) is commonly prescribed to alleviate the climacteric symptoms of menopause. Recent findings from the Women's Health Initiative has raised questions about the routine use of HRT due to the increased observed incidence of cardiovascular disease and of breast and ovarian cancers in the treatment arm of the trial. In the general population, the association between HRT use and risk of ovarian cancer has not yet been resolved. This association has not been evaluated in BRCA1 or BRCA2 mutation carriers who face very high lifetime risks of both breast and ovarian cancers. Methods. We conducted a matched case-control study on 162 matched sets of women who carry a deleterious mutation in either the BRCA1 or BRCA2 gene. Women who had been diagnosed with ovarian cancer were matched to control subjects by mutation, year of birth, and age at menopause. Information on HRT use was derived from a questionnaire routinely administered to women who were found to be carriers of a mutation in either gene. Conditional logistic regression was used to estimate the association between HRT use and the risk of ovarian cancer, stratified by mutation status and type of HRT. Results. Compared with those who had never used HRT, the odds ratio associated with ever use of HRT was 0.93 (95{\%} CI = 0.56-1.56). There was no significant relationship with increasing duration of HRT use. There was a suggestion that progestin-based HRT regimens might protect against ovarian cancer (odds ratio = 0.57) but this association was not statistically significant (P = 0.20). Conclusion. HRT use does not appear to adversely influence the risk of ovarian cancer in BRCA mutation carriers.",
author = "Joanne Kotsopoulos and Jan Lubinski and Neuhausen, {Susan L.} and Lynch, {Henry T.} and Barry Rosen and Peter Ainsworth and Pal Moller and Parviz Ghadirian and Claudine Isaacs and Beth Karlan and Ping Sun and Narod, {Steven A.}",
year = "2006",
month = "1",
doi = "10.1016/j.ygyno.2005.07.110",
language = "English",
volume = "100",
pages = "83--88",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

AU - Kotsopoulos, Joanne

AU - Lubinski, Jan

AU - Neuhausen, Susan L.

AU - Lynch, Henry T.

AU - Rosen, Barry

AU - Ainsworth, Peter

AU - Moller, Pal

AU - Ghadirian, Parviz

AU - Isaacs, Claudine

AU - Karlan, Beth

AU - Sun, Ping

AU - Narod, Steven A.

PY - 2006/1

Y1 - 2006/1

N2 - Objective. Hormone replacement therapy (HRT) is commonly prescribed to alleviate the climacteric symptoms of menopause. Recent findings from the Women's Health Initiative has raised questions about the routine use of HRT due to the increased observed incidence of cardiovascular disease and of breast and ovarian cancers in the treatment arm of the trial. In the general population, the association between HRT use and risk of ovarian cancer has not yet been resolved. This association has not been evaluated in BRCA1 or BRCA2 mutation carriers who face very high lifetime risks of both breast and ovarian cancers. Methods. We conducted a matched case-control study on 162 matched sets of women who carry a deleterious mutation in either the BRCA1 or BRCA2 gene. Women who had been diagnosed with ovarian cancer were matched to control subjects by mutation, year of birth, and age at menopause. Information on HRT use was derived from a questionnaire routinely administered to women who were found to be carriers of a mutation in either gene. Conditional logistic regression was used to estimate the association between HRT use and the risk of ovarian cancer, stratified by mutation status and type of HRT. Results. Compared with those who had never used HRT, the odds ratio associated with ever use of HRT was 0.93 (95% CI = 0.56-1.56). There was no significant relationship with increasing duration of HRT use. There was a suggestion that progestin-based HRT regimens might protect against ovarian cancer (odds ratio = 0.57) but this association was not statistically significant (P = 0.20). Conclusion. HRT use does not appear to adversely influence the risk of ovarian cancer in BRCA mutation carriers.

AB - Objective. Hormone replacement therapy (HRT) is commonly prescribed to alleviate the climacteric symptoms of menopause. Recent findings from the Women's Health Initiative has raised questions about the routine use of HRT due to the increased observed incidence of cardiovascular disease and of breast and ovarian cancers in the treatment arm of the trial. In the general population, the association between HRT use and risk of ovarian cancer has not yet been resolved. This association has not been evaluated in BRCA1 or BRCA2 mutation carriers who face very high lifetime risks of both breast and ovarian cancers. Methods. We conducted a matched case-control study on 162 matched sets of women who carry a deleterious mutation in either the BRCA1 or BRCA2 gene. Women who had been diagnosed with ovarian cancer were matched to control subjects by mutation, year of birth, and age at menopause. Information on HRT use was derived from a questionnaire routinely administered to women who were found to be carriers of a mutation in either gene. Conditional logistic regression was used to estimate the association between HRT use and the risk of ovarian cancer, stratified by mutation status and type of HRT. Results. Compared with those who had never used HRT, the odds ratio associated with ever use of HRT was 0.93 (95% CI = 0.56-1.56). There was no significant relationship with increasing duration of HRT use. There was a suggestion that progestin-based HRT regimens might protect against ovarian cancer (odds ratio = 0.57) but this association was not statistically significant (P = 0.20). Conclusion. HRT use does not appear to adversely influence the risk of ovarian cancer in BRCA mutation carriers.

UR - http://www.scopus.com/inward/record.url?scp=29144432292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144432292&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2005.07.110

DO - 10.1016/j.ygyno.2005.07.110

M3 - Article

C2 - 16137751

AN - SCOPUS:29144432292

VL - 100

SP - 83

EP - 88

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -